OM:EQTCapital Markets
How EQT’s Buybacks and Tubulis Exit May Reshape EQT (OM:EQT) Investors’ Capital Recycling Story
In early April 2026, EQT AB continued its ongoing share repurchase program on Nasdaq Stockholm, while EQT Life Sciences agreed to sell its minority stake in clinical-stage biotech Tubulis to Gilead Sciences for up to US$5.00 billion, with Tubulis becoming a dedicated antibody-drug conjugate research unit within Gilead.
This combination of capital return through buybacks and a large healthcare exit underlines how EQT seeks to reinforce its fee-earning platform by recycling realized capital...